Ye Xiong

Ye Xiong

Auto-generated profile, based on publicly available information

Ye Xiong

Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
SCSandra J. Casak
Sandra J. Casak
SPShan Pradhan
Shan Pradhan
LFLola A. Fashoyin-Aje
Lola A. Fashoyin-Aje
YRYi Ren
Yi Ren
YSYuan-Li Shen
Yuan-Li Shen
SLSteven J. Lemery
Steven J. Lemery
On August 25, 2021, the FDA approved ivosidenib for the treatment of adult patients with unresectable locally advanced or metastatic hepatocellular isocitrate dehydrogenase 1 (IDH1) mutated cholangiocarcinoma (CCA) as detected by an FDA-approved test with disease progression after 1 to 2 prior lines of systemic therapy for advanced disease. The approval was based on data from Study AG120-C-005 (ClarIDHy), a double-blind placebo-controlled trial that randomly allocated (2:1) patients to receive either ivosidenib or placebo. Independently assessed progression-free survival (PFS) was the primary endpoint. With a median follow-up of 6.9 months, the HR for PFS was 0.37 [95% confidence interval (CI), 0.25–0.54; P < 0.0001). Overall survival (OS) was the key secondary endpoint. At the final analysis of OS, with 70.5% of patients in the placebo arm receiving ivosidenib post disease progression, a non–statistically significant improvement in the ivosidenib arm with an HR = 0.79 (95% CI, 0.56–1.12) and median OS of 10.3 months (95% CI, 7.8–12.4) and 7.5 months (95% CI, 4.8–11.1) in the ivosidenib and placebo arms, respectively, were reported. Adverse reactions occurring in >20% of patients receiving ivosidenib were fatigue/asthenia, nausea, diarrhea, abdominal pain, ascites, vomiting, cough, and decreased appetite. Adverse reactions occurring in >20% of patients receiving placebo were fatigue/asthenia, nausea, abdominal pain, and vomiting. This is the first approval for the subset of patients with CCA harboring an IDH1 mutation.

25 August 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
SSSonia Singh
Sonia Singh
DBDiana Bradford
Diana Bradford
XLXiaoxue Li
Xiaoxue Li
PMPallavi S. Mishra-Kalyani
Pallavi S. Mishra-Kalyani
YSYuan-Li Shen
Yuan-Li Shen
MDMartha Donoghue
Martha Donoghue
On April 5, 2022, FDA granted accelerated approval to alpelisib for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-related overgrowth spectrum (PROS) who require systemic therapy. Efficacy was evaluated using real-world data (RWD) from EPIK-P1 (NCT04285723), a single-arm clinical study in patients 2 years of age and older with severe or life-threatening PROS who received alpelisib as part of an expanded access program (EAP) for compassionate use. The primary endpoint was confirmed radiologic response rate at week 24 as determined by blinded independent central review (BICR), using volumetric-based criteria given the atypical growth pattern and irregular shape of PROS lesions. Radiologic response was defined as a ≥20% reduction from baseline in the sum of measurable target lesion volume in up to three lesions. Of the 37 patients in the efficacy population, 27% [95% confidence interval (CI), 14–44] had a radiologic response at week 24. Duration of response (DOR) was an additional efficacy outcome measure, and among responders, 60% had a response lasting ≥12 months. Furthermore, supportive clinical documentation suggested early signals of clinical benefit (i.e., improvement in PROS-related signs and symptoms). The most common (≥10%) adverse reactions were diarrhea, stomatitis, and hyperglycemia.

14 January 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
SSSonia Singh
Sonia Singh
DBDiana Bradford
Diana Bradford
SCSomak Chatterjee
Somak Chatterjee
XLXiaoxue Li
Xiaoxue Li
SAStephanie L. Aungst
Stephanie L. Aungst
NDNicole Drezner
Nicole Drezner
On April 23, 2024, the FDA granted accelerated approval to tovorafenib, a type II RAF kinase inhibitor, for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (pLGG) harboring a BRAF fusion or rearrangement or BRAF V600 mutation. Efficacy was evaluated in FIREFLY-1 (NCT04775485), a single-arm, open-label, multicenter trial that enrolled patients 6 months to 25 years of age with relapsed or refractory pLGG with an activating BRAF alteration who had received prior systemic therapy. The major efficacy outcome measure was the radiologic overall response rate, defined as the proportion of patients with complete response, partial response, or minor response as determined by blinded independent central review using Response Assessment in Pediatric Neuro-Oncology criteria. A key secondary endpoint was duration of response. In an efficacy population of 76 patients, the overall response rate was 51% (95% confidence interval, 40–63), and the median duration of response was 13.8 months (95% confidence interval, 11.3–not estimable). The required postmarketing clinical trial (FIREFLY-2) was well underway at the time of accelerated approval. This represents the first FDA approval of a systemic therapy for the treatment of patients with pLGG with BRAF fusions or rearrangements.

5 September 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
MBMichael I. Barbato
Michael I. Barbato
ABAmy K. Barone
Amy K. Barone
SAStephanie L. Aungst
Stephanie L. Aungst
CMClaudia P. Miller
Claudia P. Miller
SASuryatheja Ananthula
Suryatheja Ananthula
NDNicole Drezner
Nicole Drezner
On August 6, 2024, the FDA granted traditional approval to vorasidenib (Voranigo, Servier Pharmaceuticals, LLC) for the treatment of adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase 1 or 2 mutation following surgery, including biopsy, subtotal resection, or gross total resection. The approval was based on data from a randomized, multicenter, double-blind trial of vorasidenib compared with placebo. The primary objective was to demonstrate the efficacy of vorasidenib based on radiographic progression-free survival (PFS) per blinded independent central review according to the modified Response Assessment for Neuro-oncology for Low-Grade Gliomas criteria. PFS was assessed in 331 patients, and the HR was 0.39 (95% confidence interval, 0.27–0.56; P value < 0.0001). The most common (≥15%) adverse reactions included fatigue, headache, COVID-19, musculoskeletal pain, diarrhea, nausea, and seizure. PFS was considered an appropriate endpoint for this disease, considering the long natural history and the randomized design allowed for the interpretation of the treatment effect in this rare malignancy. This was the first FDA approval for a targeted therapy for isocitrate dehydrogenase-mutant grade 2 gliomas.

25 September 2025 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
XYXuefen Yin
Xuefen Yin
YXYe Xiong
Ye Xiong
YBYouwei Bi
Youwei Bi
XWXin Wei
Xin Wei
HZHong Zhao
Hong Zhao
JLJiang Liu
Jiang Liu
Conventional exposure–response (E–R) analyses, such as logistic regression and time‐to‐event analysis using summary exposure metrics, are often conducted in oncology using data from the pivotal trial(s) with a single dose level to support dosing decisions. However, these E–R analyses, affected by multiple confounding factors, may mischaracterize true E–R relationships, potentially limiting their utility in dosing decisions. This study investigates potential mischaracterization in such analyses influenced by the following time‐dependent confounding factors: exposure accumulation, dose modification patterns, and event onset time. We used a simulation‐based approach to evaluate two E–R scenarios: ER1, where event time generated with a Weibull distribution is not affected by drug exposure, and ER2, where the response is driven by drug exposure via a joint PK‐tumor size model. Our analyses indicate that when using time‐dependent exposure metrics (e.g., average concentration till event/censoring), exposure accumulation tends to induce an inverse E–R trend, while dose modifications (interruptions/reductions) likely induce a positive E–R trend. Simulations suggest that employing static exposure metrics (e.g., first‐cycle or steady‐state) minimizes these biases. Additionally, adopting an E max model aligned with the underground truth in ER2 in the E–R analyses could reduce bias. When significant dose modifications are present, including relevant data from a dose‐range study and employing modified methods for time‐dependent exposure derivation may help mitigate bias. Overall, using multiple exposure metrics (including static ones) to assess E–R consistency and interpreting the potential causal effects with totality of evidence (including dose–response results) should be implemented to better inform dosing decisions.

13 May 2025
Verified
Other
Open access
SSSonia Singh
Sonia Singh
DBDiana Bradford
Diana Bradford
SCSomak Chatterjee
Somak Chatterjee
XLXiaoxue Li
Xiaoxue Li
SAStephanie L. Aungst
Stephanie L. Aungst
NDNicole Drezner
Nicole Drezner
Table S1 shows select laboratory abnormalities of at least 20% in frequency that worsened from baseline in patients with pediatric low-grade glioma who received tovorafenib in FIREFLY-1.